Abstract
Context. Canagliflozin has been reported to increase the risk of bone fracture – possibly mediated by decreasing 1,25-dihydroxyvitamin D [1,25(OH)2D] and increasing PTH.
Objective. To investigate whether baseline vitamin D (VitD) deficiency renders individuals vulnerable to this adverse effect and whether VitD3 supplementation is protective.
Design. This study had a paired design comparing individual participants before and after VitD3 supplementation.
Setting. Community-based outpatient.
Patients. 11 VitD deficient (25-hydroxyvitamin D [25(OH)D] ≤ 20 ng/mL) individuals recruited from the Amish population in Lancaster PA.
Interventions. Participants underwent two canagliflozin challenge protocols (300 mg daily for five days): the first before and the second after VitD3 supplementation. In the VitD3 supplementation protocol, participants received VitD3 supplementation (50,000 IU once or twice a week depending on BMI for 4-6 weeks) to achieve 25(OH)D ≥ 30 ng/mL.
Main Outcome Measures. Two co-primary endpoints were identified: effects of VitD3 supplementation on canagliflozin-induced changes in 1,25(OH)2D and PTH. Secondary endpoints included effects of VitD3 supplementation on baseline levels of VitD metabolites and PTH.
Results. VitD3 supplementation increased mean 25(OH)D from 16.5±1.6 to 44.3±5.5 ng/mL (p=0.0006) and 24,25-dihydroxyvitamin D [24,25(OH)2D] from 1.0±0.1 to 4.3±0.6 ng/mL (p=0.0002). Mean 1,25(OH)2D and PTH were unchanged. VitD3 supplementation decreased the magnitude of canagliflozin-induced changes in 1,25(OH)2D (from −31.3%±4.7% to −9.3%±8.3%; p=0.04) and PTH (from +36.2%±6.2% to +9.7%±3.7%; p=0.005).
Conclusions. VitD deficiency rendered individuals more vulnerable to adverse effects of canagliflozin on biomarkers associated with bone health. VitD3 supplementation was protective against canagliflozin’s short-term adverse effects on 1,25(OH)2D and PTH.
Competing Interest Statement
SIT serves as a consultant for Ionis Pharmaceuticals and receives an inventors share of royalties from NIDDK for metreleptin as a treatment for generalized lipodystrophy. EAS, MEM, and HBW receive research support (unrelated to this project) from the Regeneron Genetics Center. ZSY and ALB have no conflicts to disclose.
Clinical Trial
NCT02891954
Funding Statement
Funding from NIDDK and the NIH Office of Dietary Supplements: R01DK118942, R01DK118942-02S1, and T32DK098107
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
University of Maryland Baltimore Institutional Review Board
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Funding: R01DK118942, R01DK118942-02S1, and T32DK098107
Disclosure summary: SIT serves as a consultant for Ionis Pharmaceuticals and receives an inventor’s share of royalties from NIDDK for metreleptin as a treatment for generalized lipodystrophy. EAS, MEM, and HBW receive research support (unrelated to this project) from the Regeneron Genetics Center. ZSY and ALB have no conflicts to disclose.
The discussion section has been expanded to address questions and comments that have arisen during the course of the review process.
